{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:05:31Z","timestamp":1779408331813,"version":"3.53.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-04964-4","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T09:25:15Z","timestamp":1775899515000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of the effects of non-calcium and calcium-based phosphate binders on fibroblast growth factor-23 levels in patients with CKD\u2013mineral and bone disorder: a meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"27","author":[{"given":"Seunghyun","family":"Cha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyoung","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choungwon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"issue":"11","key":"4964_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Dr\u00fceke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945\u201353. https:\/\/doi.org\/10.1038\/sj.ki.5000414.","journal-title":"Kidney Int"},{"issue":"11","key":"4964_CR2","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1001\/jama.2011.308","volume":"305","author":"SC Palmer","year":"2011","unstructured":"Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011;305(11):1119\u201327. https:\/\/doi.org\/10.1001\/jama.2011.308.","journal-title":"JAMA"},{"issue":"1","key":"4964_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1185\/03007995.2013.841667","volume":"30","author":"RG Kalaitzidis","year":"2014","unstructured":"Kalaitzidis RG, Elisaf MS. Hyperphosphatemia and phosphate binders: effectiveness and safety. Curr Med Res Opin. 2014;30(1):109\u201312. https:\/\/doi.org\/10.1185\/03007995.2013.841667.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"4964_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1146\/annurev.med.051308.111339","volume":"61","author":"C Bergwitz","year":"2010","unstructured":"Bergwitz C, J\u00fcppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med. 2010;61(1):91\u2013104. https:\/\/doi.org\/10.1146\/annurev.med.051308.111339.","journal-title":"Annu. Rev. Med"},{"issue":"3","key":"4964_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41581-022-00665-x","volume":"19","author":"R Agoro","year":"2023","unstructured":"Agoro R, White KE. Regulation of FGF23 production and phosphate metabolism by bone\u2013kidney interactions. Nat Rev Nephrol. 2023;19(3):185\u201393. https:\/\/doi.org\/10.1038\/s41581-022-00665-x.","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"4964_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00424-022-02668-w","volume":"474","author":"S Rausch","year":"2022","unstructured":"Rausch S, F\u00f6ller M. The regulation of FGF23 under physiological and pathophysiological conditions. Pflugers Arch - Eur J Physiol. 2022, Mar;474(3):281\u201392. https:\/\/doi.org\/10.1007\/s00424-022-02668-w.","journal-title":"Pflugers Arch - Eur J Physiol"},{"issue":"2","key":"4964_CR7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3346\/jkms.2017.32.2.240","volume":"32","author":"CS Kim","year":"2017","unstructured":"Kim CS, Bae EH, Ma SK, Han SH, Lee KB, Lee J, et al. Chronic kidney disease-mineral bone disorder in Korean patients: a report from the Korean cohort study for outcomes in patients with chronic kidney disease (KNOW-CKD). J Korean Med Sci. 2017;32(2):240\u201348. https:\/\/doi.org\/10.3346\/jkms.2017.32.2.240.","journal-title":"J Korean Med Sci"},{"issue":"4","key":"4964_CR8","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.21037\/apm-21-1943","volume":"11","author":"SJ Zhao","year":"2022","unstructured":"Zhao SJ, Wang ZX, Chen L, Wang FX, Kong LD. Effect of different phosphate binders on fibroblast growth factor 23 levels in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Ann Palliat Med. 2022;11(4):1264\u201377. https:\/\/doi.org\/10.21037\/apm-21-1943.","journal-title":"Ann Palliat Med"},{"issue":"2","key":"4964_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11255-021-02848-0","volume":"54","author":"K Takkavatakarn","year":"2022","unstructured":"Takkavatakarn K, Wuttiputhanun T, Phannajit J, Praditpornsilpa K, Eiam-Ong S, Susantitaphong P. Effectiveness of fibroblast growth factor 23 lowering modalities in chronic kidney disease: a systematic review and meta-analysis. Int Urol Nephrol. 2022;54(2):309\u201321. https:\/\/doi.org\/10.1007\/s11255-021-02848-0.","journal-title":"Int Urol Nephrol"},{"issue":"5","key":"4964_CR10","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1007\/s10157-016-1362-9","volume":"21","author":"YM Chang","year":"2017","unstructured":"Chang YM, Tsai SC, Shiao CC, Liou HH, Yang CL, Tung NY, et al. Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients. Clin Exp Nephrol. 2017;21(5):908\u201316. https:\/\/doi.org\/10.1007\/s10157-016-1362-9.","journal-title":"Clin Exp Nephrol"},{"issue":"11","key":"4964_CR11","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1681\/ASN.2020040411","volume":"31","author":"ND Toussaint","year":"2020","unstructured":"Toussaint ND, Pedagogos E, Lioufas NM, Elder GJ, Pascoe EM, Badve SV, et al. A randomized trial on the effect of phosphate reduction on vascular end points in CKD (IMPROVE-CKD). J Am Soc Nephrol. 2020;31(11):2653\u201366. https:\/\/doi.org\/10.1681\/ASN.2020040411.","journal-title":"J Am Soc Nephrol"},{"key":"4964_CR12","doi-asserted-by":"publisher","unstructured":"Cancela ALE, Oliveira RB, Graciolli FG, dos Reis LM, Barreto F, Barreto DV, et al. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron Clin Pract. 2010;117(1):c74\u201382. https:\/\/doi.org\/10.1159\/000319650.","DOI":"10.1159\/000319650"},{"issue":"8","key":"4964_CR13","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1681\/ASN.2012030223","volume":"23","author":"GA Block","year":"2012","unstructured":"Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012;23(8):1407\u201315. https:\/\/doi.org\/10.1681\/ASN.2012030223.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"4964_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.kint.2024.11.013","volume":"107","author":"M Ketteler","year":"2025","unstructured":"Ketteler M, Evenepoel P, Holden RM, Isakova T, J\u00f8rgensen HS, Komaba H, et al. Chronic kidney disease\u2013mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2025;107(3):405\u201323. https:\/\/doi.org\/10.1016\/j.kint.2024.11.013.","journal-title":"Kidney Int"},{"key":"4964_CR15","unstructured":"Chapter 6.5.2. Cochrane Information Specialists, authors. Review: abstract and plain language summary. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. editors. Cochrane Handbook for systematic reviews of interventions. London: Cochrane; updated 2024 Aug. p. 2024. https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-06#section-6-5-2."},{"key":"4964_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135. https:\/\/doi.org\/10.1186\/1471-2288-14-135.","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"4964_CR17","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","volume":"27","author":"D Luo","year":"2018","unstructured":"Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785\u2013805. https:\/\/doi.org\/10.1177\/0962280216669183.","journal-title":"Stat Methods Med Res"},{"issue":"2","key":"4964_CR18","doi-asserted-by":"publisher","first-page":"286","DOI":"10.2215\/CJN.05420709","volume":"5","author":"RB Oliveira","year":"2010","unstructured":"Oliveira RB, Cancela ALE, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol. 2010;5(2):286\u201391. https:\/\/doi.org\/10.2215\/CJN.05420709.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"09","key":"4964_CR19","doi-asserted-by":"publisher","first-page":"216","DOI":"10.5414\/CN107257","volume":"78","author":"T Toida","year":"2012","unstructured":"Toida T, Fukudome K, Fujimoto S, Yamada K, Sato Y, Chiyotanda S, et al. Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study. Clin Nephrol. 2012;78(09):216\u201323. https:\/\/doi.org\/10.5414\/CN107257.","journal-title":"Clin Nephrol"},{"issue":"6","key":"4964_CR20","doi-asserted-by":"publisher","first-page":"934","DOI":"10.2215\/CJN.12891211","volume":"7","author":"H Vlassara","year":"2012","unstructured":"Vlassara H, Uribarri J, Cai W, Goodman S, Pyzik R, Post J, et al. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol. 2012;7(6):934\u201342. https:\/\/doi.org\/10.2215\/CJN.12891211.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"07","key":"4964_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5414\/CN107764","volume":"80","author":"S Soriano","year":"2013","unstructured":"Soriano S, Ojeda R, Rodr\u00edguez M, Almad\u00e9n Y, Rodr\u00edguez M, Mart\u00edn-Malo A, et al. The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients. Clin Nephrol. 2013;80(07):17\u201322. https:\/\/doi.org\/10.5414\/CN107764.","journal-title":"Clin Nephrol"},{"issue":"45","key":"4964_CR22","doi-asserted-by":"publisher","first-page":"e8664","DOI":"10.1097\/MD.0000000000008664","volume":"96","author":"C Zhang","year":"2017","unstructured":"Zhang C, Wang S, Zhao S, Zhang X. Effect of lanthanum carbonate on coronary artery calcification and bone mineral density in maintenance hemodialysis patients with diabetes complicated with adynamic bone disease: a prospective pilot study. Med (Baltim). 2017;96(45):e8664. https:\/\/doi.org\/10.1097\/MD.0000000000008664.","journal-title":"Med (Baltim)"},{"issue":"2","key":"4964_CR23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/cts.13151","volume":"15","author":"DL Mason","year":"2022","unstructured":"Mason DL, Godugu K, Nnani D, Mousa SA. Effects of sevelamer carbonate versus calcium acetate on vascular calcification, inflammation, and endothelial dysfunction in chronic kidney disease. Clin Transl Sci. 2022;15(2):353\u201360. https:\/\/doi.org\/10.1111\/cts.13151.","journal-title":"Clin Transl Sci"},{"issue":"4","key":"4964_CR24","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.ekir.2018.03.011","volume":"3","author":"CP Kovesdy","year":"2018","unstructured":"Kovesdy CP, Lu JL, Wall BM, Gyamlani G, Naseer A, Wallick A, et al. Changes with lanthanum carbonate, calcium acetate, and phosphorus restriction in CKD: a randomized controlled trial. Kidney Int Rep. 2018;3(4):897\u2013904. https:\/\/doi.org\/10.1016\/j.ekir.2018.03.011.","journal-title":"Kidney Int Rep"},{"issue":"9","key":"4964_CR25","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1093\/ndt\/gft203","volume":"28","author":"A Covic","year":"2013","unstructured":"Covic A, Passlick-Deetjen J, Kroczak M, B\u00fcschges-Seraphin B, Ghenu A, Ponce P, et al. A comparison of calcium acetate\/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrol Dial Transpl. 2013;28(9):2383\u201392. https:\/\/doi.org\/10.1093\/ndt\/gft203.","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"4964_CR26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1053\/j.ajkd.2011.11.007","volume":"59","author":"MI Yilmaz","year":"2012","unstructured":"Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis. 2012;59(2):177\u201385. https:\/\/doi.org\/10.1053\/j.ajkd.2011.11.007.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"4964_CR27","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1681\/ASN.2013050465","volume":"25","author":"JJ Scialla","year":"2014","unstructured":"Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, et al. Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol. 2014;25(2):349\u201360. https:\/\/doi.org\/10.1681\/ASN.2013050465.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"4964_CR28","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S2213-8587(17)30310-8","volume":"6","author":"A Covic","year":"2018","unstructured":"Covic A, Vervloet M, Massy ZA, Torres PU, Goldsmith D, Brandenburg V, et al. Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. Lancet Diabetes Endocrinol. 2018;6(4):319\u201331. https:\/\/doi.org\/10.1016\/S2213-8587(17)30310-8.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"4964_CR29","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/ki.2011.47","volume":"79","author":"T Isakova","year":"2011","unstructured":"Isakova T, Wahl P, Vargas GS, Guti\u00e9rrez OM, Scialla J, Xie H, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79(12):1370\u201378. https:\/\/doi.org\/10.1038\/ki.2011.47.","journal-title":"Kidney Int"},{"issue":"19","key":"4964_CR30","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","volume":"119","author":"OM Guti\u00e9rrez","year":"2009","unstructured":"Guti\u00e9rrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009;119(19):2545\u201352. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.844506.","journal-title":"Circulation"},{"issue":"23","key":"4964_CR31","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1001\/jama.2011.826","volume":"305","author":"T Isakova","year":"2011","unstructured":"Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011;305(23):2432\u201339. https:\/\/doi.org\/10.1001\/jama.2011.826.","journal-title":"JAMA"},{"key":"4964_CR32","doi-asserted-by":"publisher","unstructured":"KDIGO. 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1\u201359. https:\/\/doi.org\/10.1016\/j.kisu.2017.04.001.","DOI":"10.1016\/j.kisu.2017.04.001"},{"issue":"1","key":"4964_CR33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/0971-4065.177137","volume":"27","author":"U Anandh","year":"2017","unstructured":"Anandh U, Mandavkar P, Das B, Rao S. Fibroblast growth factor-23 levels in maintenance hemodialysis patients in India. Indian J Nephrol. 2017;27(1):9\u201312. https:\/\/doi.org\/10.4103\/0971-4065.177137.","journal-title":"Indian J Nephrol"},{"issue":"6","key":"4964_CR34","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMoa0706130","volume":"359","author":"OM Guti\u00e9rrez","year":"2008","unstructured":"Guti\u00e9rrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008, Aug;359(6):584\u201392. https:\/\/doi.org\/10.1056\/NEJMoa0706130.","journal-title":"N Engl J Med"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04964-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04964-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04964-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T23:06:10Z","timestamp":1779404770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04964-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4964"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04964-4","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"323"}}